Skip to content

Combine and Conquer: Minimizing the Impact of Toxicity Associated with Novel Immunotherapy-Angiogenesis Inhibitor Combinations
Renal Cell Carcinoma Fireside Chat *Post-Test*

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.
1.Where are you in your career?(Required.)
2.Which of the following is a common high-grade toxicity associated with the use of TKIs in the management of metastatic RCC?(Required.)
3.Which of the following is NOT a characteristic of immune-mediated toxicities associated with the use of ICIs?(Required.)
4.A patient treated with the combination of pembrolizumab and lenvatinib for metastatic RCC develops grade 3 diarrhea. How might you diagnose which drug is causing this toxicity?(Required.)
5.A patient treated with the combination of cabozantinib and nivolumab develops grade 3 hypertension. Cabozantinib therapy is held and the patient receives anti-hypertensive medication and their BP recovers to baseline. At what dose can cabozantinib be restarted?(Required.)
EVALUATION FORM
6.Upon completion of this activity, I am able to:
Strongly agree
Agree
Disagree
Strongly disagree
EXPRESS awareness of AEs associated with anti-angiogenic therapy and how they differ from immune-mediated AEs
DIFFERENTIATE etiology and presentation of overlapping toxicities with AA/IO combination therapy
SELECT optimal strategies to prevent and manage common AEs experienced by patients treated with AA/IO combination therapy
7.Please indicate the extent of your agreement with the following statements:
Strongly agree
Agree
Disagree
Strongly disagree
The faculty for this activity were effective
The educational resources and/or handouts provided to me at the educational activity are useful to my practice
8.Overall, was this activity fair, balanced and free from commercial bias?
9.If no, please explain:
10.Of the patients you will see in the next month, about how many will benefit from the information you learned today?
11.Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):
12.Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):
13.For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*(Required.)
14.I certify that I have participated in the continuing education activity entitled, "Combine and Conquer: Minimizing the Impact of Toxicity Associated with Novel Immunotherapy-Angiogenesis Inhibitor Combinations | Renal Cell Carcinoma Fireside Chat" and claim 0.5 AMA PRA Category 1 CreditTM.(Required.)
Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate. 

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Privacy & Cookie Notice